Sadiq Khan has put £22m into three London projects on heart disease, blood pressure and quantum technology, with £98m more pledged in match funding.
Three London projects working on heart disease, high blood pressure and quantum technology will share £22m of public money, the Mayor of London, Sadiq Khan, announced on Monday 16 November, the opening day of London Life Sciences Week. City Hall says more than £98m in match funding, including pledged contributions, has been lined up alongside it, taking the combined investment past £120m.
Overview
- What: £22m from London’s share of the Local Innovation Partnerships Fund, a UK Research and Innovation (UKRI) programme worth up to £500m across the UK.
- Who gets it: a King’s College London and BioInnovation Institute venture builder (£5m), the PHIX London health technology project led by UCLPartners (£5m), and the London Quantum Cluster (£12m).
- What is left: London’s allocation is £30m, so about £8m is still to be handed out. City Hall says it will be allocated in due course.
- Barnet’s part: none of the three projects is based in the borough, and Barnet is not among the councils named as partners.
Where the money goes
Two of the three projects are aimed at cardiometabolic disease: obesity, diabetes and heart disease. City Hall calls these a leading cause of death and of health inequality in London, falling hardest on people on lower incomes.
The first, a venture builder co-led by the BioInnovation Institute and King’s College London, will receive £5m to turn heart and metabolic research into new businesses developing treatments and medical technology, including ways to detect heart disease earlier.
The second, PHIX London, gets £5m. It is led by UCLPartners and works with NHS and private providers in the Harley Street Health District to help companies test new health technology and bring it into wider use, including better ways to detect and monitor high blood pressure and irregular heart rhythms. Its delivery partners are listed as Harley Street Health District, AlbionVC and London’s three health innovation networks.
The largest award, £12m, continues the London Quantum Cluster, founded by UCL, Imperial College London and King’s College London. It is based in the Knowledge Quarter around King’s Cross, Bloomsbury and Euston, and across the WestTech London area in the west of the capital, and will help companies test quantum technology for use in healthcare, transport, finance, energy and defence. Its industry partners include IBM, Nvidia, Amazon and Quantinuum. The councils named as partners are Hammersmith and Fulham, Camden and Islington.
Why blood pressure is the target
The release puts a number on what is at stake. Targeted improvements in treating high blood pressure alone, City Hall says, could prevent more than 1,200 heart attacks, 1,800 strokes and almost 1,000 deaths in London, and save the NHS around £46m and social care £12m.
Professor Kevin Fenton, Regional Director of Public Health for NHS London and OHID London, said preventing cardiovascular disease “is one of London’s biggest public health priorities”. The two heart projects, he said, “connect research, venture development, clinical testing and NHS implementation, helping promising discoveries reach the people and communities who need them most. Together, they could strengthen London’s Million Hearts and Minds prevention programme, reduce inequalities and position London as a global leader in cardiovascular innovation.”
City Hall adds that the funding supports its ambition for London to become a Health Innovation Zone, bringing the NHS, researchers and businesses together, starting with heart health.
What the Mayor said
Speaking at the launch of the week, Sadiq Khan was expected to say: “London is one of the most exciting life sciences hubs in the world, thanks to our unique combination of world-leading research, clinical innovation and commercial expertise. But now we want to go even further and make London not just the European capital for life sciences, but the world capital.”
He called the £22m “a new shot in the arm” for the sector, adding: “Our commitment has also helped unlock nearly £100 million in match funding, sparking a chain reaction of investment that will create jobs, drive growth and fast-track innovation.”
Professor Sir Ian Chapman, UKRI’s chief executive, said the fund’s investments would build on “the strength and depth of expertise, talented people and innovative companies in London”. Laura Citron, chief executive of London & Partners and chair of the Frontier Innovation Board, which chose the funding priorities, said helping London’s ideas succeed “also means creating exciting careers, especially in new industries like quantum.”
What it means for you
There is nothing for Barnet residents to apply for: the grants went to three consortiums chosen through an open call run by the Greater London Authority and assessed by an independent panel convened by UKRI. UKRI and the GLA will manage the grants.
The closest effect is on jobs and treatment. The quantum and research work is concentrated around Euston and King’s Cross, a direct Northern line ride from High Barnet, Finchley, Hendon and Edgware, and the heart projects are designed to move new tests and treatments into NHS use across London.
City Hall’s wider figures for the sector: more than 2,700 life sciences companies in London, around 40,000 jobs, and $3.2bn raised in venture capital so far in 2026, 35 per cent more than in the whole of 2025, according to Dealroom figures analysed by London & Partners. London Life Sciences Week, run by the UK BioIndustry Association, MedCity and London & Partners, is expected to bring more than 5,000 industry leaders, innovators and investors to the capital.
Source: Mayor of London press office.
Have your say